June 17 2022 Acip Meeting

Safety, immunogenicity and efficacy of BNT162b2 in children ages 6 months through 4 years of age; mRNA COVID-19 vaccines in ... Introduction; Epidemiology of COVID-19 in young children; Updates on vaccine effectiveness of COVID-19 vaccines in children ... Moderna COVID-19 vaccine (mRNA-1273): Safety, immunogenicity and efficacy in children ages 6 months through 5 years of age. Introduction; Vaccine effectiveness update; Influenza vaccination of older adults; Summary, work group considerations, and ... Cost effectiveness models ,Considerations for the use of herpes zoster vaccines, Impact of the U.S. varicella vaccination program ... Introduction; PCV15 Pediatric Clinical Development Program – Update; Economic analysis and public health Impact of PCV15 ...

Novavax COVID-19 vaccine: Safety, immunogenicity and efficacy in adults ages 18 years and older. Introduction; Implementation of pediatric vaccines; Evidence to recommendation Framework: mRNA COVID-19 vaccine in young ... Introduction,GRADE: Evidence for Use of MenB Vaccines in Adolescents and Young Adults (including College Students),Public ... Zostavax Phase IV study; Zostavax GRADE; Herpes Zoster vaccine revaccination data Comments on this video are allowed in ... Updates to Clinical Considerations; Canadian experience and evidence with COVID-19 vaccine primary series extended intervals ... Introduction by Dr. L Rubin. Immunogenicity and safety of MenACWY-CRM by Dr. P Dull. GRADE (grading of evidence) for ...

Proposed changes in the 2018 adult immunization schedule; Proposed 2018 child and adolescent schedule revisions; JE among ...